Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20642297 | 0.88 | LMNA (0.32) | GABRA1GABRB1LMNAP2RX3P2RX2 | |
| SCHEMBL10272986 | 0.80 | GAA (0.34) | HTTCYP1A2POLBPTGS1PTGS2 | |
| SCHEMBL15417381 | 0.79 | NOS3 (0.38) | LMNACYP1A2POLB | |
| SCHEMBL20642322 | 0.78 | NOS3 (0.33) | CYP1A2POLB | |
| SCHEMBL22448740 | 0.78 | P2RX3 (0.35) | P2RX3P2RX2CYP1A2POLB | |
| SCHEMBL20288204 | 0.77 | NOS3 (0.35) | CYP1A2POLBPTGS1PTGS2 | |
| SCHEMBL20642453 | 0.76 | TLR9 (0.36) | P2RX3P2RX2 | |
| SCHEMBL25795554 | 0.76 | LMNA (0.36) | GABRA1GABRB1LMNACYP1A2POLB | |
| SCHEMBL16502348 | 0.75 | PGK1 (0.37) | CYP1A2POLBPTGS1PTGS2 | |
| SCHEMBL18353218 | 0.73 | GABRA1 (0.39) | GABRA1GABRB1LMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PTPN5, PTPN1, PTPN2 | GABRA1 3202/4885GABRB1 3774/4885LMNA 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.